July 24, 2015 8:36 AM | 1 min read |
27% profit every 20 days?
This is what Nic Chahine averages with his option buys. Not selling covered calls or spreads… BUYING options. Most traders don’t even have a winning percentage of 27% buying options. He has an 83% win rate. Here’s how he does it.
Shares of
27% profit every 20 days?
This is what Nic Chahine averages with his option buys. Not selling covered calls or spreads… BUYING options. Most traders don’t even have a winning percentage of 27% buying options. He has an 83% win rate. Here’s how he does it.
(NYSE: ABBV) declined more than 2 percent in pre-market trading after the company reported downbeat sales for the second quarter. However, the company's profit exceeded analysts' estimates. The North Chicago, Illinois-based company reported a quarterly net profit of $1.37 billion, or $0.83 per share, compared to $1.1 billion, or $0.68 per share, in the year-ago quarter. Excluding non-recurring items, the company's adjusted earnings came in at $1.08 per share. Its revenue climbed 11.1 percent to $5.48 billion, while sales an operational basis surged 19.4 percent. Analysts were expecting earnings of $1.06 per share on revenue of $5.62 billion. The average estimate among 23 Estimize users was for earnings of $1.06 per share and revenue of $5.59 billion.Its sales of Humira rose 7.6 percent to $3.54 billion. Adjusted operating margin in the second quarter widened to 44.2 percent, from 36.4 percent in the year-ago quarter.Adjusted research and development in the quarter was 15.9 percent of sales."We are pleased with the high level of performance we've delivered through the first-half of 2015, consistent with our commitment to shareholders for top-tier growth this year and beyond," said Richard A. Gonzalez, chairman and chief executive officer, AbbVie. "With the completion of the Pharmacyclics transaction, continued momentum from our on-market products and rapid evolution of our robust development pipeline, we are well positioned to deliver strong performance in the future."AbbVie reaffirmed its FY15 adjusted earnings forecast of $4.10 to $4.30 per share, versus analysts' estimates of $4.24 per share.AbbVie shares fell 2.86 percent to $68.50 in pre-market trading.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.